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Background: One of diabetic complications involves apoptosis of cardiomyocytes. microRNAs are novel biomarkers, modulators and therapeutic 
targets for heart disease. The microRNAs miR-1 is preferentially expressed in cardiac muscles. Insulin-like growth factor (IGF-1), one of cardiac 
protective factors, induces survival of multiple cell types.
Methods: Diabetes was induced in ApoE-/- mice by injecting low doses of streptozotocin. Diabetic ApoE-/- mice received treatment with either 
IGF-1 infusion or sham infusion, with or without miR-1 mimics.
Results: Induction of diabetes in ApoE-/- mice was associated with early development of both systolic (ejection fraction and fractional shortening) 
and diastolic dysfunction (E/A ratio) which was accompanied by increased rate of cardiac apoptosis and fibrosis. In diabetic hearts, we found 
that increased expression of miR-1 determined by the mirVana qRT-PCR miRNA detection assay, and decreased expression of IGF-1 determined by 
Western blot. IGF-1 infusion restored systolic and diastolic dysfunction in diabetic ApoE-/- mice determined by Echocardiography. The improvement 
of cardiac function by IGF-1 treatment was associated with reduced rates of cardiac apoptosis (TUNEL assay) and fibrosis (Massion’s trichrome 
staining). Western blot analysis showed IGF-1 treatment decreased levels of pro-apoptotic proteins cytochrome C, caspase 3 and Bax, but increased 
levels of anti-apoptotic protein bcl-2 and connexin-43 in heart. miR-1 mimics blocked the effects of IGF-1 infusion. Using prediction algorithms, we 
identified 3’-untranslated regions of IGF-1 gene are the target of miR-1. Moreover, overexpression of specific miR-1 mimics blocked the capacity of 
the IGF-1 to prevent glucose-induced mitochondrial dysfunction, cytochrome C release and apoptosis in cardiomyocyte cell line H9C2.
Conclusions: IGF-1 prevented diabetes induced cardiomyopathy via a marked anti-apoptosis and anti-fibrosis effects, which are mediated by 
miR-1. These findings provide a new paradigm for the endocrine effects of IGF-1 in heart, and suggest that cardiac specific miR-1 may be a useful 
biomarker and therapeutic target for diabetes-induced cardiomyopathy.
